Immutep to focus Efti development on HNSCC with CPS < 1 and neoadjuvant STS
IMMP•Efti development focus narrowed
- Immutep said it will focus Efti development on HNSCC with CPS < 1 and neoadjuvant STS.
- The company also said it has contracted a new manufacturing run of Efti at 200 L scale.
- Immutep targets the start of its next Efti clinical trials in 2H CY2027.
